Evidence map›Paper›PMID 35843966›Full record

ArticleEuropean journal of hybrid imaging2022

Daniela A Ferraro, Andreas M Hötker, Anton S Becker, Iliana Mebert, Riccardo Laudicella, Anka Baltensperger, Niels J Rupp, Jan H Rueschoff, Julian Müller, Ashkan Mortezavi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of hybrid imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. International EANM-SNMMI-ISMRM consensus recommendation for PET/MRI in oncology.European journal of nuclear medicine and molecular imaging · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Daniela A Ferraro *Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Andreas M Hötker *Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Anton S BeckerDiagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Iliana MebertDepartment of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Riccardo LaudicellaDepartment of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Anka BaltenspergerDepartment of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Niels J RuppDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Jan H RueschoffDepartment of Pathology and Molecular Pathology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Julian MüllerDepartment of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
Ashkan MortezaviDepartment of Urology, University Hospital Zürich, University of Zurich, Zurich, Switzerland.
Marcelo T SapienzaDepartment of Radiology and Oncology, Faculdade de Medicina FMUSP, Universidade de São Paulo, São Paulo, Brazil.
Daniel EberliDepartment of Urology, University Hospital Zürich, University of Zurich, Zurich, Switzerland.
Olivio F Donati *Diagnostic and Interventional Radiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Irene A Burger *Department of Nuclear Medicine, University Hospital Zürich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland. irene.burger@usz.ch.ORCID http://orcid.org/0000-0001-8029-8692

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748NCI NIH HHS P30CA008748
6 · The paper itself

Abstract

backgroundMagnetic resonance imaging (MRI) is recommended by the European Urology Association guidelines as the standard modality for imaging-guided biopsy. Recently positron emission tomography with prostate-specific membrane antigen (PSMA PET) has shown promising results as a tool for this purpose. The aim of this study was to compare the accuracy of positron emission tomography with prostate-specific membrane antigen/magnetic resonance imaging (PET/MRI) using the gallium-labeled prostate-specific membrane antigen (

resultsSensitivity and specificity were 61.4% and 92.9% for mpMRI and 66.7% and 92.9% for PSMA PET/MRI for reader one, respectively. RPE was available in 23 patients and 41 of 47 quadrants with discrepant findings. Based on RPE results, the specificity for both imaging modalities increased to 98% and 99%, and the sensitivity improved to 63.9% and 72.1% for mpMRI and PSMA PET/MRI, respectively. Both modalities yielded a substantial interreader agreement for primary tumour localization (mpMRI kappa = 0.65 (0.52-0.79), PSMA PET/MRI kappa = 0.73 (0.61-0.84)). ICC for SUV

conclusionsPSMA PET/MRI has similar accuracy and reliability to mpMRI regarding primary prostate cancer (PCa) localization. In our cohort, semiquantitative parameters from PSMA PET/MRI correlated with tumour grade and were more reliable than the ones from mpMRI.

Indexed as

ADCBiopsy guidanceInterreader agreementmpMRIPET/MRIPrimary stagingPSMA PETSUVmaxTargeted biopsyTemplate biopsy

Identifiers

PMID35843966
PMCPMC9288941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.